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S U M M A R Y
Objectives: Hepatitis delta virus (HDV) is recognized as the most pathogenic and infectious among the
hepatotropic viruses. Studies on the treatment of HDV have predominantly included European patients
and carriers of genotype 1 (HDV-1) in their clinical protocols. For the Amazon region, data show that
infected individuals have mainly Native American ancestry and that >90% of HDV carriers have the
genotype 3 (HDV-3). Thus combined therapy clinical protocols do not adequately address the treatment
of these patients.
Methods: A prospective, non-randomized study was conducted in which 22 patients received 180 mg of
pegylated interferon alpha 2a (PEG-IFN) plus entecavir at a dose of 0.5 mg for 48 weeks, with a
subsequent 24-week follow-up. Throughout treatment, the patients were monitored for biochemical
responses and the kinetics of hepatitis B virus (HBV) and HDV viral loads.
Results: Of the 22 patients treated, 15 presented normal alanine aminotransferase values at the end of
treatment (p = 0.002). At week 24 of treatment, 86.4% of the patients did not present detectable HDV-
RNA; at week 48, the rate of negative patients increased to >95% and remained the same after 6 months.
With regard to HBV, only two patients (9%) still presented detectable HBV genetic material at the end of
treatment, suggesting the effectiveness of combined therapy in combating the two viruses.
Conclusions: These ﬁndings support the use of this effective therapeutic protocol for HDV-3 in patients of
non-European ethnicity and suggest a possible ‘easy to treat’ variant when compared to HDV-1.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Hepatitis delta virus (HDV) was identiﬁed by Rizzetto et al.
upon examination of the liver biopsies of patients infected with
hepatitis B virus (HBV) presenting abnormal symptoms of severe
liver disease.1 This virus is recognized as the most pathogenic and
infectious among the hepatotropic viruses.2
Millions of people are susceptible to infection as a result of
already being carriers of HBV, and as the replication of HDV cannot
be inhibited with the same drugs used for mono-infected patients,* Corresponding author. Tel.: +55 069 3219 6012; fax: +55 069 3219 6000.
E-mail address: juanitto2001@yahoo.com.br (J.M.V. Salcedo).
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the search for an effective treatment is essential. Some authors
have reported the efﬁcacy and safety of pegylated interferon (PEG-
IFN) use in patients with chronic hepatitis delta. However, the
results obtained after treatment were extremely variable, making
it difﬁcult to assess the true impact of interferon (standard or
pegylated) on the course of this severe liver disease.3–6
The fact that combination therapy increases the effectiveness in
the treatment of co-infections of HBV and hepatitis C virus (HCV),7
led to the investigation of whether or not the association of
conventional interferon alpha (IFN-a) with lamivudine (or ribavirin)
would also be beneﬁcial for the treatment of chronic hepatitis delta.
A small increase in the virological response was obtained in patients
treated with conventional IFN-a plus lamivudine (28%) compared to
those treated with IFN alone (17%), but the difference was not
statistically signiﬁcant.8 Based on this evidence, new articles have
emerged suggesting that combination therapy for HBV and HDV isciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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with oral antivirals used in the treatment of HBV infection has
become an alternative therapeutic protocol (named combined
therapy), and some clinical studies have suggested several
advantages when compared to IFN treatment alone.10–12 The
mechanisms involved in this approach are not known, but it is
suggested that the suppression of viral replication for prolonged
periods decreases the chances of hepatic decompensation.10
These prior studies have two important shortcomings. The ﬁrst
is with respect to the population studied. Although the virus
presents a worldwide distribution, the patients recruited in
already published studies have predominantly been Cauca-
sian.12–17 Since Brazil shows a more heterogeneous trend in
ethnic groups, the present study population comprised Caucasians,
Native Americans, and blacks.18,19
The second concerns the prevailing HDV genotype, which could
interfere with combination therapy. It is known that the different
genotypes can lead to different clinical outcomes and that HDV
genotype 3 (HDV-3) is associated with more severe forms of the
disease.20 Despite the apparent participation of the genotype in
cases of fulminant hepatitis, the inﬂuence of the genotype on the
course of treatment has not been veriﬁed as with other hepatotropic
infections (i.e., HBV and HCV); these other hepatotropic infectionsFigure 1. Flowchart showing the monitoring ohave presented different responses to treatment with PEG-IFN
according to the viral genotype.21–23
As there is no effective therapy for chronic hepatitis delta
patients and patients in the authors’ outpatient setting have a
different epidemiological proﬁle from those included in other
reports, it was sought to assess the efﬁcacy of treatment with PEG-
IFN combined with a nucleoside analog (entecavir) in the
treatment of chronic hepatitis delta, as well as to correlate the
response to treatment with genotype 3 of the virus (HDV-3).
2. Methods
2.1. Study population and experimental design
This study was approved by the local ethics committee (process
number CAAE 0012.0.046.000-11, 2011/Set/09). Informed consent
was obtained from each patient.
A prospective, non-randomized study was performed with a
treatment regimen of 48 weeks in duration for 22 selected patients
(Figure 1). Throughout the treatment period, 180 mg of pegylated
interferon alpha 2a (PEG-IFN) was administered subcutaneously
once a week along with the nucleotide analog entecavir at an oral
dose of 0.5 mg daily.f patients during the therapeutic protocol.
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strict supervision by the research team. The following inclusion
criteria were established: (1) age >18 and <70 years, (2) serological
diagnosis of infection with HBV and HDV, (3) PCR positive for genetic
material from HDV, (4) no antiviral therapy used in the past
6 months, (5) the patient had to present a ﬂoating or persistent
elevation of alanine aminotransferase (ALT) on at least two
occasions in the 3 months leading up to the start of treatment,
(6) the patient had to present compensated liver disease classiﬁed as
Child–Pugh A <7 points or MELD <12, (7) the patient had to be
negative for hepatocellular carcinoma, and (8) the patient had to
present laboratory criteria that would allow the use of PEG-IFN.
Exclusion criteria were the following: (1) pregnant women or
those who did not acknowledge contraceptive control, (2) patients
who had been treated with PEG-IFN in the 6 months preceding the
start of the study, (3) patients who had used nucleos(t)ide analogs
in the 12 weeks preceding the study, (4) patients who had
undergone anticancer or immunomodulatory therapies in the
5 years prior to the start of the study, (5) those with a positive test
for hepatitis A virus (HAV) IgM antibodies, (6) those testing
positive for antibodies to HIV 1 or 2 (anti-HIV), (7) patients with a
history or clinical evidence of other concomitant liver disease, (8)
those with autoimmune diseases, alcoholic liver disease, or
exposure to toxins, (9) alcohol consumption higher than 30 g
per day, (10) those with decompensated liver cirrhosis, (11) any
other ongoing decompensated disease such as heart disease,
diabetes mellitus, etc., (12) hemophiliac patients, (13) patients
with psychiatric disorders considered serious (evaluation with
psychiatric report), (14) patients with chronic renal failure, (15)
patients with neutropenia, carriers of hemoglobinopathies, and/or
hemolytic anemia, and (16) patients with other diseases that
would prevent them from complying with the established
protocol.
2.2. Clinical monitoring
A treatment period of 48 weeks was completed and a
subsequent 24-week follow-up was performed. Possible adverse
reactions to medications such as itching, nausea, vomiting,
diarrhea, headache, and leukopenia were also monitored, and
the patients were assessed and treated according to the reaction
presented.
2.3. Hematological and biochemical tests
Patients were monitored as outpatients and, when necessary,
complete blood count, prothrombin time, direct bilirubin, creatinine,
alkaline phosphatase, gamma-glutamyl transferase, urea, aspartate
aminotransferase, and blood glucose tests were performed.
In addition to these procedures, the patients had blood
collected in the pre-treatment weeks and at 4, 12, 24, and
48 weeks post-treatment for the quantiﬁcation of the ALT enzyme
(normal value considered to be below 35 U/l).
2.4. Serological tests
Immediately before starting treatment, all patientswere tested for
the detection of the following viral markers using the ELISA technique
in accordance with the manufacturer’s instructions: hepatitis B
surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B e
antibody (anti-HBe), and total HDV antibodies (anti-HDV).
2.5. Histological evaluation
Twenty-two patients underwent percutaneous liver core
needle biopsy blindly. All liver specimens were fragments largerthan 2 cm; these were ﬁxed in 10% formalin and later embedded in
parafﬁn. The histopathological technique consisted of serial
histological sections stained with hematoxylin–eosin, comple-
mented with separate sections stained with the following special
stains: PAS (periodic acid–Schiff) with diastase, reticulin, picrosir-
ius, Perls, and orcein.24 The material collected was satisfactory for
18 patients. The liver biopsy results of these 18 patients were
reviewed according to the METAVIR classiﬁcation,25 which is able
to evaluate the different degrees of inﬂammation and ﬁbrosis.
2.6. Viral load
For this study, the methodology described by dos Santos et al.
was used to determine the HBV load (sensitivity of 20 IU/ml).26 To
monitor HDV, the quantiﬁcation method described by Botelho-
Souza et al. was used (sensitivity of 75 copies/ml of viral RNA).27
Some of the samples were sent at random to the Genome Center in
Sa˜o Paulo for external control and to validate the results.
2.7. Genotyping of HDV
For the determination of the HDV genotype, all of the previous
procedures described by Botelho-Souza et al. were followed,
including primers, cycle conditions, nucleotide sequencing, and
phylogenetic analysis.18
2.8. Statistical analysis
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) was
used for the statistical analysis, as well as the design of the graphs.
Quantitative values were recorded as medians and statistical
differences were assessed using several parametric and non-
parametric tests, including column statistics, the t-test, Pearson’s
correlation, and two-way analysis of variance (ANOVA), as
appropriate. For analyses of qualitative data, the Chi-square test
was used. Differences were considered signiﬁcant at p < 0.05.
3. Results
3.1. Patient population
Twenty-two patient began treatment between July 2011 and
July 2012. Detailed patient characteristics are presented in
Table 1. All patients were treated simultaneously for HBV and
HDV for 48 weeks. Of these 22 patients, none abandoned treatment
or died before completion at week 48. No patient failed to attend
follow-up during the 24 post-treatment weeks. Because this is an
endemic region there was no association with risk factors such as
the use of intravenous drugs, blood transfusions, or tattoos. No
patient was working as a healthcare professional.
Serological tests were performed pre-treatment and all patients
presented positive HBsAg, negative hepatitis B surface antibodies
(anti-HBs), negative HBeAg, positive anti-HBe, positive anti-HDV
IgG, negative HCV antibodies (anti-HCV), and negative anti-HIV.
3.2. Dual therapy side effects
The most common adverse reactions were related to the
administration of PEG-IFN. Arthralgia, myalgia, and asthenia were
reported in all patients. Weight loss was observed in 83% of
patients, with a mean weight loss of 5 kg during treatment.
Headache, epigastric pain, and fever were reported by 50% of
patients, and other less frequent symptoms such as diarrhea and
dizziness were also mentioned. The drugs used for symptomatic
relief, when present, were dipyrone (at a dose of 500 mg orally
every 6 h for those with no history of allergy to this medication),
Table 1
Patient characteristics







Native American 12 52




Biopsy characteristics Number %
Activity (A)
A 1 3 16
A 2 10 55
A 3 5 29
Fibrosis (F)
F 1 7 39
F 2 5 28
F 3 5 28
F 4 1 5















Previous treatment 0 0
HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; HBV, hepatitis B virus;
HDV, hepatitis delta virus; ALT, alanine aminotransferase.
a Mean values.
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a dose of 40 mg orally once daily), and metoclopramide (at a dose
of 10 mg orally every 8 h).
Throughout treatment, the patients were monitored at the
frequency stipulated in the protocol. No reported adverse eventsFigure 2. Reduction in the amount of alanine aminotransferase (ALT; IU/l) measured in th
treatment; the Wilcoxon test was used (p = 0.002). (B) The median of all 22 treated patien
24 weeks, and 48 weeks of treatment, and at 6 months after the end of treatment; Pewere considered serious enough to require dose adjustment or
justify the suspension of medications.
3.3. Treatment outcomes
3.3.1. Biochemical response
Due to laboratory differences, ALT value results of less than
35 U/l were treated as normal. Of the 22 patients treated,
15 presented normal values at the end of treatment and 14 out of
15 maintained a biochemical response after 24 weeks of follow-up.
Comparing the pre- and post-treatment analyses, a p-value of
0.0015 was obtained (Figure 2A).
Regarding ﬂuctuations in the enzyme (Figure 2B), it was found
that the desired values began to be achieved after 48 weeks of
treatment and remained in tests conducted at 24 weeks after the
completion of treatment. Among the patients who did not achieve
normal values, six showed a reduction in ALT at the end of treatment,
four showed a steady increase of between 10 and 50 U/l during
treatment, and ALT levels remained stable in two (data not shown).
3.3.2. Kinetics of viral loads
The HDV and HBV viral loads of the patients were evaluated at
time points considered important to evaluate the prognosis.17
Thus, the patient viral loads were analyzed during the pre-
treatment period, at 24 weeks after the start of the treatment
(week 24), at 48 weeks after the start of treatment (week 48), and
at 24 weeks after the end of treatment, as detailed in Table 2.
At week 24, 82.6% of the patients no longer presented detectable
HDV-RNA, and at the subsequent time points, the rate of negative
patients increased to values >95%, remaining the same at 6 months
after treatment completion. Only one subject was positive until the
end of treatment, but the amount of genetic material detected for
this patient at 24 weeks after the completion of treatment was about
half the pre-treatment value. Figure 3 shows the dynamics of the
HDV viral load tracking for each individual patient.
With regard to HBV, 15 patients (60%) had replicating HBV; at
week 24, the number of patients with a detectable viral load
decreased to nine individuals. At the end of treatment, only two
patients (9%) still presented detectable genetic material, suggesting
the effectiveness of combined therapy in combating the two viruses.
Figure 4 shows the kinetics of the two viruses, suggesting that
combination therapy of PEG-IFN with entecavir inhibits HBV from
multiplying when the amount of HDV decreases.e patients’ serum. (A) Quantiﬁcation of patients pre-treatment and at 6 months post-
ts whose sera were quantiﬁed in the weeks before treatment, at 4 weeks, 12 weeks,
arson’s correlation test showed a signiﬁcant p-value of 0.0296.
Table 2
Individually assessed kinetics of HDV and HBV viral loads
Patient number HDV, log10 copies/ml HBV, log10 IU/ml
Pre-treatment Week 24 Week 48 6 months
post- treatment
Pre-treatment Week 24 Week 48 6 months
post- treatment
1 4.58 3.47 2.60 2.63 0.00 2.51 2.51 0.00
2 4.13 0.00 0.00 0.00 7.28 0.00 0.00 0.00
3 3.83 0.00 0.00 0.00 2.83 2.55 1.89 0.00
4 5.54 0.00 0.00 0.00 0.00 3.57 2.42 0.00
5 3.02 0.00 0.00 0.00 0.00 0.00 0.00 3.15
6 2.24 2.21 0.00 0.00 3.91 2.15 1.26 6.36
7 4.28 5.03 0.00 0.00 7.82 1.70 2.16 0.00
8 4.22 0.00 0.00 0.00 2.99 0.00 0.00 0.00
9 3.74 0.00 0.00 0.00 2.30 2.47 2.41 0.00
10 2.45 0.00 0.00 0.00 3.51 0.00 1.85 0.00
11 5.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00
12 3.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00
13 2.06 0.00 0.00 0.00 2.37 1.78 1.88 0.00
14 3.32 0.00 0.00 0.00 2.00 0.00 0.00 0.00
15 4.31 0.00 0.00 0.00 2.76 0.00 0.00 0.00
16 5.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00
17 4.64 0.00 0.00 0.00 2.32 0.00 0.00 0.00
18 3.53 0.00 0.00 0.00 2.74 0.00 0.00 0.00
19 4.85 0.00 0.00 0.00 3.04 0.00 0.00 0.00
20 3.05 0.00 0.00 0.00 1.96 0.00 0.00 0.00
21 3.77 0.00 0.00 0.00 2.58 0.00 0.00 0.00
22 4.07 0.00 0.00 0.00 0.00 1.93 2.01 0.00
HDV, hepatitis delta virus; HBV, hepatitis B virus.
Figure 3. The individual analysis of each patient using the Wilcoxon test, showing
p < 0.0001 between the pre-treatment week and week 24, where one can notice the
absence of viral load in 18 of the 22 patients.
Figure 4. Monitoring of the average viral loads of HDV and HBV during the pre-
treatment phase (Pre), at 24 weeks and 48 weeks of treatment, and at 6 months
post-treatment (Post). The total number of patients included in these results ranged
from a minimum of 18 to a maximum of 22, depending on the availability of
biological material. There was no correlation between the HBV and HDV loads.
However, the t-test showed a p-value of 0.0065 between the different treatment
times, showing a signiﬁcant reduction in viral load for both viruses over time.
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In the Amazon, hepatitis delta is considered a neglected disease
associated with high morbidity and mortality epidemics that
rapidly leads to chronicity, cirrhosis, and hepatocarcinoma.28 It is
believed that several factors lead to this clinical condition, such as
poor access to health centers, low education level, poor hygiene
conditions, and the high prevalence of HDV-3 in the region.18 In
addition to these factors, there is a lack of published studies on the
efﬁcacy and safety of the clinical protocol of combination therapy
used in patients who are not of the European standard (male,
Caucasian, with HDV -1).12–17 This has led to a clinical gap with
regard to the type of follow-up that patients from the Amazon
region should follow.
Thus, the initial design of this clinical trial was followed by a
total of 22 patients who entirely fulﬁlled the characteristics
advocated in the inclusion criteria for the selection of the project
population. This sample size is similar to those used in otherpublished studies, for example that by Grabowski et al., who
assessed PEG-IFN associated with adefovir in 17 patients,14 that by
Castelnau et al., who treated hepatitis delta in 14 patients,4 and
that by Niro et al., who completed a study on PEG-IFN alone in
16 patients.29
Epidemiologically, the present ﬁndings shed some light on the
type of patient found outside of Europe. It was observed that the
patients tolerated the side effects of PEG-IFN well and did not require
dose adjustments. Regarding sex, it has been reported that female
sex is associated with clinical decompensation during the follow-up
period;30 however this was not corroborated in the present study
since men and women responded to the treatment in the same way.
Regarding the race of the patients, it was found that Native
American descendants represented more than half of the patients
(52%) in this study, which may have been a differential in the high
virological response rates achieved. A recent study analyzed the
presence of different polymorphisms in several cytokines respon-
sible for a predominantly Th1 response pattern in this ethnic
L.M.P. Borzacov et al. / International Journal of Infectious Diseases 46 (2016) 82–88 87group.31 It is not known how these single nucleotide polymor-
phisms (SNPs) are passed to future generations, nor the inﬂuence
of ancestry on the present work. However, the authors do not
believe that the ethnicity factor was predominant, since the other
43% of patients who responded to treatment had different
ethnicities.
Another population data point concerns cirrhotic patients.
Thirty-three percent of patients in the study had advanced ﬁbrosis
(F3 and F4). These patients were clinically stable before the start of
therapy, classiﬁed as Child–Pugh A and with calculated MELD scores
below 12. The percentage of cirrhotic patients in the present study
was higher than that reported in some other studies. Previous
studies have reported varying percentages of cirrhotic patients:
Castelnau et al. included 29% of patients with this condition,4
Yurdaydin et al. studied a population in which approximately 35%
had cirrhosis,32 and Niro et al. reported approximately 75% of
participating patients as being cirrhotic.29 However, these studies
reported a much lower virological response than that found in the
present study (30%, 13%, and 21%, respectively), which suggests that
patients with cirrhosis have a higher chance of being null or poor
responders, thus presenting a lower virological response than
patients without advanced ﬁbrosis.
ALT levels are proposed to represent a good marker of the
prognosis in these patients. In laboratory tests performed before
treatment, it was observed that the values were above normal
(>35 IU/l) in 20 out of 22 patients, indicating potential liver
damage from HBV/HDV. The normalization of this biochemical
parameter occurred at the end of week 48 in 14 patients, and 12 of
these patients continued with ALT levels within the normal range.
Other studies have presented higher values when compared to
those in the present study.4,17,33 However, in the most recently
published study it can be seen that patients who responded to
treatment showed lower levels.17 The only non-responding
patient, patient 1, presented a ﬂoating ALT, and post-treatment
follow-up showed values of 47 IU/l. Thus, the present study also
found that this increase in ALT after the end of treatment is
suggestive of a relationship with increasing HBV/HDV viral loads,
ultimately suggesting that liver damage continues to occur even
with medication.
Regarding the monitoring of viral load, all patients who showed
undetectable HDV at week 24 (p < 0.0001) continued to show this
until treatment was completed and also during follow-up. On
comparing these ﬁndings to those reported in the single article that
correlates viral load and prognosis, it appears that the data are
consistent with those described by the authors.17 In addition, since
there were only three patients who were still positive at week 48,
and only one patient who did not become negative, it was not
possible to perform a statistical analysis on exact values expected
in week 24, but it is possible to suggest that the article by Keskin
et al.17 can be extrapolated to genotype 3.
These ﬁndings help strengthen the idea that combination therapy
is effective in the treatment of HDV-3 in patients of non-European
ethnicity. However, to obtain an answer above initial expectations,
future studies should be conducted in collaboration with other places
so that it can be demonstrated whether or not HDV-3 is an ‘easy to
treat’ variant when compared to genotype 1. Regardless of future
studies, this is the ﬁrst study to demonstrate an effective therapeutic
protocol that can be followed in patients with genotype 3.
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